IMAGO BIOSCIENCES INC (IMGO) Fundamental Analysis & Valuation

NASDAQ:IMGO • US45250K1079

36.01 USD
+0.01 (+0.03%)
At close: Jan 10, 2023
36.01 USD
0 (0%)
After Hours: 1/10/2023, 8:15:28 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This IMGO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

IMGO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IMGO as it has an excellent financial health rating, but there are worries on the profitability. IMGO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. IMGO Profitability Analysis

1.1 Basic Checks

  • In the past year IMGO has reported negative net income.
  • IMGO had a negative operating cash flow in the past year.
IMGO Yearly Net Income VS EBIT VS OCF VS FCFIMGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 -10M -20M -30M -40M

1.2 Ratios

  • The profitability ratios for IMGO are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMGO Yearly ROA, ROE, ROICIMGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 -100 -200 -300

1.3 Margins

  • IMGO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMGO Yearly Profit, Operating, Gross MarginsIMGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. IMGO Health Analysis

2.1 Basic Checks

  • IMGO has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for IMGO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IMGO Yearly Shares OutstandingIMGO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 10M 20M 30M
IMGO Yearly Total Debt VS Total AssetsIMGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 51.58 indicates that IMGO is not in any danger for bankruptcy at the moment.
  • IMGO has a better Altman-Z score (51.58) than 98.60% of its industry peers.
  • IMGO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 51.58
ROIC/WACCN/A
WACCN/A
IMGO Yearly LT Debt VS Equity VS FCFIMGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 0 50M 100M 150M 200M

2.3 Liquidity

  • IMGO has a Current Ratio of 13.16. This indicates that IMGO is financially healthy and has no problem in meeting its short term obligations.
  • IMGO has a better Current ratio (13.16) than 80.72% of its industry peers.
  • IMGO has a Quick Ratio of 13.16. This indicates that IMGO is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of IMGO (13.16) is better than 80.72% of its industry peers.
Industry RankSector Rank
Current Ratio 13.16
Quick Ratio 13.16
IMGO Yearly Current Assets VS Current LiabilitesIMGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. IMGO Growth Analysis

3.1 Past

  • IMGO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -69.94%.
EPS 1Y (TTM)-69.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 8.80% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y46.56%
EPS Next 2Y14.27%
EPS Next 3Y6.87%
EPS Next 5Y8.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMGO Yearly EPS VS EstimatesIMGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. IMGO Valuation Analysis

4.1 Price/Earnings Ratio

  • IMGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMGO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMGO Price Earnings VS Forward Price EarningsIMGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMGO Per share dataIMGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.27%
EPS Next 3Y6.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IMGO Dividend Analysis

5.1 Amount

  • IMGO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

IMGO Fundamentals: All Metrics, Ratios and Statistics

IMAGO BIOSCIENCES INC

NASDAQ:IMGO (1/10/2023, 8:15:28 PM)

After market: 36.01 0 (0%)

36.01

+0.01 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners8.93%
Ins Owner Change0%
Market Cap1.22B
Revenue(TTM)N/A
Net Income(TTM)-61.64M
Analysts50.91
Price Target36.72 (1.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.58%
Min EPS beat(2)-10.45%
Max EPS beat(2)19.61%
EPS beat(4)1
Avg EPS beat(4)-3.86%
Min EPS beat(4)-13.41%
Max EPS beat(4)19.61%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.06
P/tB 7.06
EV/EBITDA N/A
EPS(TTM)-1.84
EYN/A
EPS(NY)-2.56
Fwd EYN/A
FCF(TTM)-1.55
FCFYN/A
OCF(TTM)-1.55
OCFYN/A
SpS0
BVpS5.1
TBVpS5.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.16
Quick Ratio 13.16
Altman-Z 51.58
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-69.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.64%
EPS Next Y46.56%
EPS Next 2Y14.27%
EPS Next 3Y6.87%
EPS Next 5Y8.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-134.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-134.7%
OCF growth 3YN/A
OCF growth 5YN/A

IMAGO BIOSCIENCES INC / IMGO FAQ

What is the fundamental rating for IMGO stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMGO.


What is the valuation status for IMGO stock?

ChartMill assigns a valuation rating of 1 / 10 to IMAGO BIOSCIENCES INC (IMGO). This can be considered as Overvalued.


How profitable is IMAGO BIOSCIENCES INC (IMGO) stock?

IMAGO BIOSCIENCES INC (IMGO) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for IMGO stock?

The Earnings per Share (EPS) of IMAGO BIOSCIENCES INC (IMGO) is expected to grow by 46.56% in the next year.